nodes	percent_of_prediction	percent_of_DWPC	metapath
Almotriptan—CYP3A4—Thiotepa—urinary bladder cancer	0.0664	0.191	CbGbCtD
Almotriptan—CYP2E1—Etoposide—urinary bladder cancer	0.0594	0.17	CbGbCtD
Almotriptan—CYP2C8—Fluorouracil—urinary bladder cancer	0.0531	0.153	CbGbCtD
Almotriptan—CYP2C8—Etoposide—urinary bladder cancer	0.0444	0.127	CbGbCtD
Almotriptan—CYP1A2—Fluorouracil—urinary bladder cancer	0.0411	0.118	CbGbCtD
Almotriptan—CYP1A2—Etoposide—urinary bladder cancer	0.0343	0.0986	CbGbCtD
Almotriptan—FMO3—urine—urinary bladder cancer	0.0217	0.189	CbGeAlD
Almotriptan—CYP2D6—Doxorubicin—urinary bladder cancer	0.0193	0.0554	CbGbCtD
Almotriptan—CYP3A4—Etoposide—urinary bladder cancer	0.018	0.0517	CbGbCtD
Almotriptan—CYP3A4—Doxorubicin—urinary bladder cancer	0.0123	0.0352	CbGbCtD
Almotriptan—CYP2C19—urine—urinary bladder cancer	0.00959	0.0834	CbGeAlD
Almotriptan—Melatonin—MT3—urinary bladder cancer	0.00842	0.688	CrCbGaD
Almotriptan—CYP1A2—urine—urinary bladder cancer	0.00783	0.0681	CbGeAlD
Almotriptan—FMO3—prostate gland—urinary bladder cancer	0.00779	0.0677	CbGeAlD
Almotriptan—CYP2E1—urine—urinary bladder cancer	0.00705	0.0613	CbGeAlD
Almotriptan—CYP3A4—urine—urinary bladder cancer	0.00567	0.0493	CbGeAlD
Almotriptan—CYP2D6—urine—urinary bladder cancer	0.00558	0.0485	CbGeAlD
Almotriptan—FMO3—vagina—urinary bladder cancer	0.00385	0.0334	CbGeAlD
Almotriptan—MAOA—prostate gland—urinary bladder cancer	0.00337	0.0293	CbGeAlD
Almotriptan—MAOA—seminal vesicle—urinary bladder cancer	0.00285	0.0248	CbGeAlD
Almotriptan—CYP2E1—prostate gland—urinary bladder cancer	0.00253	0.022	CbGeAlD
Almotriptan—HTR1B—female reproductive system—urinary bladder cancer	0.0025	0.0217	CbGeAlD
Almotriptan—FMO3—lymph node—urinary bladder cancer	0.00249	0.0216	CbGeAlD
Almotriptan—HTR1D—female reproductive system—urinary bladder cancer	0.00242	0.021	CbGeAlD
Almotriptan—MAOA—renal system—urinary bladder cancer	0.0023	0.02	CbGeAlD
Almotriptan—MAOA—urethra—urinary bladder cancer	0.00226	0.0196	CbGeAlD
Almotriptan—Melatonin—MPO—urinary bladder cancer	0.00218	0.178	CrCbGaD
Almotriptan—CYP2E1—seminal vesicle—urinary bladder cancer	0.00214	0.0186	CbGeAlD
Almotriptan—CYP2C8—renal system—urinary bladder cancer	0.00205	0.0178	CbGeAlD
Almotriptan—CYP1A2—renal system—urinary bladder cancer	0.00192	0.0167	CbGeAlD
Almotriptan—MAOA—female reproductive system—urinary bladder cancer	0.00184	0.016	CbGeAlD
Almotriptan—CYP2E1—renal system—urinary bladder cancer	0.00172	0.015	CbGeAlD
Almotriptan—CYP2C19—vagina—urinary bladder cancer	0.0017	0.0148	CbGeAlD
Almotriptan—CYP2E1—urethra—urinary bladder cancer	0.00169	0.0147	CbGeAlD
Almotriptan—MAOA—vagina—urinary bladder cancer	0.00166	0.0145	CbGeAlD
Almotriptan—CYP2C8—female reproductive system—urinary bladder cancer	0.00164	0.0143	CbGeAlD
Almotriptan—Melatonin—ESR1—urinary bladder cancer	0.00164	0.134	CrCbGaD
Almotriptan—CYP2C8—vagina—urinary bladder cancer	0.00148	0.0129	CbGeAlD
Almotriptan—CYP3A4—renal system—urinary bladder cancer	0.00139	0.0121	CbGeAlD
Almotriptan—CYP2E1—female reproductive system—urinary bladder cancer	0.00138	0.012	CbGeAlD
Almotriptan—CYP2D6—renal system—urinary bladder cancer	0.00137	0.0119	CbGeAlD
Almotriptan—CYP3A4—female reproductive system—urinary bladder cancer	0.00111	0.00966	CbGeAlD
Almotriptan—CYP2D6—female reproductive system—urinary bladder cancer	0.00109	0.0095	CbGeAlD
Almotriptan—MAOA—lymph node—urinary bladder cancer	0.00108	0.00936	CbGeAlD
Almotriptan—Diarrhoea—Thiotepa—urinary bladder cancer	0.000448	0.00136	CcSEcCtD
Almotriptan—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000446	0.00135	CcSEcCtD
Almotriptan—Bronchitis—Epirubicin—urinary bladder cancer	0.000446	0.00135	CcSEcCtD
Almotriptan—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000443	0.00134	CcSEcCtD
Almotriptan—Gastritis—Doxorubicin—urinary bladder cancer	0.000439	0.00133	CcSEcCtD
Almotriptan—Pain—Cisplatin—urinary bladder cancer	0.000439	0.00133	CcSEcCtD
Almotriptan—Muscular weakness—Doxorubicin—urinary bladder cancer	0.000438	0.00133	CcSEcCtD
Almotriptan—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000435	0.00132	CcSEcCtD
Almotriptan—Dizziness—Thiotepa—urinary bladder cancer	0.000433	0.00131	CcSEcCtD
Almotriptan—Conjunctivitis—Methotrexate—urinary bladder cancer	0.000429	0.0013	CcSEcCtD
Almotriptan—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000428	0.0013	CcSEcCtD
Almotriptan—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.000423	0.00128	CcSEcCtD
Almotriptan—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000423	0.00128	CcSEcCtD
Almotriptan—Paraesthesia—Etoposide—urinary bladder cancer	0.000422	0.00128	CcSEcCtD
Almotriptan—Dyspnoea—Etoposide—urinary bladder cancer	0.000419	0.00127	CcSEcCtD
Almotriptan—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000418	0.00127	CcSEcCtD
Almotriptan—Somnolence—Etoposide—urinary bladder cancer	0.000418	0.00127	CcSEcCtD
Almotriptan—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000418	0.00127	CcSEcCtD
Almotriptan—Epistaxis—Methotrexate—urinary bladder cancer	0.000417	0.00126	CcSEcCtD
Almotriptan—Vomiting—Thiotepa—urinary bladder cancer	0.000416	0.00126	CcSEcCtD
Almotriptan—Rash—Thiotepa—urinary bladder cancer	0.000413	0.00125	CcSEcCtD
Almotriptan—Bronchitis—Doxorubicin—urinary bladder cancer	0.000412	0.00125	CcSEcCtD
Almotriptan—Dermatitis—Thiotepa—urinary bladder cancer	0.000412	0.00125	CcSEcCtD
Almotriptan—Headache—Thiotepa—urinary bladder cancer	0.00041	0.00124	CcSEcCtD
Almotriptan—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000406	0.00123	CcSEcCtD
Almotriptan—Body temperature increased—Cisplatin—urinary bladder cancer	0.000406	0.00123	CcSEcCtD
Almotriptan—Fatigue—Etoposide—urinary bladder cancer	0.000405	0.00123	CcSEcCtD
Almotriptan—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.000405	0.00123	CcSEcCtD
Almotriptan—Pain—Etoposide—urinary bladder cancer	0.000402	0.00122	CcSEcCtD
Almotriptan—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000402	0.00122	CcSEcCtD
Almotriptan—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000399	0.00121	CcSEcCtD
Almotriptan—Asthenia—Gemcitabine—urinary bladder cancer	0.000395	0.0012	CcSEcCtD
Almotriptan—Pharyngitis—Methotrexate—urinary bladder cancer	0.000393	0.00119	CcSEcCtD
Almotriptan—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000391	0.00119	CcSEcCtD
Almotriptan—Epistaxis—Epirubicin—urinary bladder cancer	0.00039	0.00118	CcSEcCtD
Almotriptan—Pruritus—Gemcitabine—urinary bladder cancer	0.00039	0.00118	CcSEcCtD
Almotriptan—Nausea—Thiotepa—urinary bladder cancer	0.000389	0.00118	CcSEcCtD
Almotriptan—Sinusitis—Epirubicin—urinary bladder cancer	0.000388	0.00118	CcSEcCtD
Almotriptan—Feeling abnormal—Etoposide—urinary bladder cancer	0.000387	0.00118	CcSEcCtD
Almotriptan—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000387	0.00117	CcSEcCtD
Almotriptan—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000385	0.00117	CcSEcCtD
Almotriptan—Pruritus—Fluorouracil—urinary bladder cancer	0.000383	0.00116	CcSEcCtD
Almotriptan—Visual impairment—Methotrexate—urinary bladder cancer	0.000382	0.00116	CcSEcCtD
Almotriptan—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000378	0.00115	CcSEcCtD
Almotriptan—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000377	0.00114	CcSEcCtD
Almotriptan—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000375	0.00114	CcSEcCtD
Almotriptan—Rhinitis—Epirubicin—urinary bladder cancer	0.000372	0.00113	CcSEcCtD
Almotriptan—Body temperature increased—Etoposide—urinary bladder cancer	0.000372	0.00113	CcSEcCtD
Almotriptan—Abdominal pain—Etoposide—urinary bladder cancer	0.000372	0.00113	CcSEcCtD
Almotriptan—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000372	0.00113	CcSEcCtD
Almotriptan—Eye disorder—Methotrexate—urinary bladder cancer	0.00037	0.00112	CcSEcCtD
Almotriptan—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00037	0.00112	CcSEcCtD
Almotriptan—Tinnitus—Methotrexate—urinary bladder cancer	0.00037	0.00112	CcSEcCtD
Almotriptan—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000369	0.00112	CcSEcCtD
Almotriptan—Asthenia—Cisplatin—urinary bladder cancer	0.000368	0.00112	CcSEcCtD
Almotriptan—Pharyngitis—Epirubicin—urinary bladder cancer	0.000368	0.00112	CcSEcCtD
Almotriptan—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000368	0.00112	CcSEcCtD
Almotriptan—Epistaxis—Doxorubicin—urinary bladder cancer	0.000361	0.00109	CcSEcCtD
Almotriptan—Sinusitis—Doxorubicin—urinary bladder cancer	0.000359	0.00109	CcSEcCtD
Almotriptan—Immune system disorder—Methotrexate—urinary bladder cancer	0.000358	0.00109	CcSEcCtD
Almotriptan—Dizziness—Fluorouracil—urinary bladder cancer	0.000358	0.00109	CcSEcCtD
Almotriptan—Visual impairment—Epirubicin—urinary bladder cancer	0.000358	0.00108	CcSEcCtD
Almotriptan—Chills—Methotrexate—urinary bladder cancer	0.000356	0.00108	CcSEcCtD
Almotriptan—Diarrhoea—Cisplatin—urinary bladder cancer	0.000351	0.00107	CcSEcCtD
Almotriptan—Vomiting—Gemcitabine—urinary bladder cancer	0.00035	0.00106	CcSEcCtD
Almotriptan—Mental disorder—Methotrexate—urinary bladder cancer	0.000347	0.00105	CcSEcCtD
Almotriptan—Rash—Gemcitabine—urinary bladder cancer	0.000347	0.00105	CcSEcCtD
Almotriptan—Dermatitis—Gemcitabine—urinary bladder cancer	0.000347	0.00105	CcSEcCtD
Almotriptan—Eye disorder—Epirubicin—urinary bladder cancer	0.000347	0.00105	CcSEcCtD
Almotriptan—Hypersensitivity—Etoposide—urinary bladder cancer	0.000346	0.00105	CcSEcCtD
Almotriptan—Tinnitus—Epirubicin—urinary bladder cancer	0.000346	0.00105	CcSEcCtD
Almotriptan—Erythema—Methotrexate—urinary bladder cancer	0.000345	0.00105	CcSEcCtD
Almotriptan—Headache—Gemcitabine—urinary bladder cancer	0.000345	0.00105	CcSEcCtD
Almotriptan—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000344	0.00104	CcSEcCtD
Almotriptan—Vomiting—Fluorouracil—urinary bladder cancer	0.000344	0.00104	CcSEcCtD
Almotriptan—Rhinitis—Doxorubicin—urinary bladder cancer	0.000344	0.00104	CcSEcCtD
Almotriptan—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000342	0.00104	CcSEcCtD
Almotriptan—Rash—Fluorouracil—urinary bladder cancer	0.000341	0.00104	CcSEcCtD
Almotriptan—Dermatitis—Fluorouracil—urinary bladder cancer	0.000341	0.00103	CcSEcCtD
Almotriptan—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000341	0.00103	CcSEcCtD
Almotriptan—Headache—Fluorouracil—urinary bladder cancer	0.000339	0.00103	CcSEcCtD
Almotriptan—Dysgeusia—Methotrexate—urinary bladder cancer	0.000338	0.00103	CcSEcCtD
Almotriptan—Asthenia—Etoposide—urinary bladder cancer	0.000337	0.00102	CcSEcCtD
Almotriptan—Immune system disorder—Epirubicin—urinary bladder cancer	0.000335	0.00102	CcSEcCtD
Almotriptan—Back pain—Methotrexate—urinary bladder cancer	0.000334	0.00101	CcSEcCtD
Almotriptan—Chills—Epirubicin—urinary bladder cancer	0.000333	0.00101	CcSEcCtD
Almotriptan—Pruritus—Etoposide—urinary bladder cancer	0.000333	0.00101	CcSEcCtD
Almotriptan—Visual impairment—Doxorubicin—urinary bladder cancer	0.000331	0.001	CcSEcCtD
Almotriptan—Nausea—Gemcitabine—urinary bladder cancer	0.000327	0.000992	CcSEcCtD
Almotriptan—Vomiting—Cisplatin—urinary bladder cancer	0.000326	0.00099	CcSEcCtD
Almotriptan—Vision blurred—Methotrexate—urinary bladder cancer	0.000325	0.000987	CcSEcCtD
Almotriptan—Mental disorder—Epirubicin—urinary bladder cancer	0.000325	0.000986	CcSEcCtD
Almotriptan—Rash—Cisplatin—urinary bladder cancer	0.000324	0.000982	CcSEcCtD
Almotriptan—Dermatitis—Cisplatin—urinary bladder cancer	0.000323	0.000981	CcSEcCtD
Almotriptan—Erythema—Epirubicin—urinary bladder cancer	0.000323	0.00098	CcSEcCtD
Almotriptan—Diarrhoea—Etoposide—urinary bladder cancer	0.000322	0.000976	CcSEcCtD
Almotriptan—Nausea—Fluorouracil—urinary bladder cancer	0.000322	0.000975	CcSEcCtD
Almotriptan—Eye disorder—Doxorubicin—urinary bladder cancer	0.000321	0.000973	CcSEcCtD
Almotriptan—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.00032	0.000971	CcSEcCtD
Almotriptan—Tinnitus—Doxorubicin—urinary bladder cancer	0.00032	0.000971	CcSEcCtD
Almotriptan—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000319	0.000966	CcSEcCtD
Almotriptan—Tension—Epirubicin—urinary bladder cancer	0.000317	0.000961	CcSEcCtD
Almotriptan—Dysgeusia—Epirubicin—urinary bladder cancer	0.000316	0.000959	CcSEcCtD
Almotriptan—Nervousness—Epirubicin—urinary bladder cancer	0.000314	0.000951	CcSEcCtD
Almotriptan—Back pain—Epirubicin—urinary bladder cancer	0.000312	0.000948	CcSEcCtD
Almotriptan—Malaise—Methotrexate—urinary bladder cancer	0.000311	0.000944	CcSEcCtD
Almotriptan—Dizziness—Etoposide—urinary bladder cancer	0.000311	0.000943	CcSEcCtD
Almotriptan—Immune system disorder—Doxorubicin—urinary bladder cancer	0.00031	0.00094	CcSEcCtD
Almotriptan—Vertigo—Methotrexate—urinary bladder cancer	0.00031	0.00094	CcSEcCtD
Almotriptan—Chills—Doxorubicin—urinary bladder cancer	0.000308	0.000934	CcSEcCtD
Almotriptan—Nausea—Cisplatin—urinary bladder cancer	0.000305	0.000925	CcSEcCtD
Almotriptan—Vision blurred—Epirubicin—urinary bladder cancer	0.000304	0.000923	CcSEcCtD
Almotriptan—Mental disorder—Doxorubicin—urinary bladder cancer	0.000301	0.000912	CcSEcCtD
Almotriptan—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.0003	0.000909	CcSEcCtD
Almotriptan—Convulsion—Methotrexate—urinary bladder cancer	0.000299	0.000907	CcSEcCtD
Almotriptan—Vomiting—Etoposide—urinary bladder cancer	0.000299	0.000907	CcSEcCtD
Almotriptan—Erythema—Doxorubicin—urinary bladder cancer	0.000299	0.000906	CcSEcCtD
Almotriptan—Agitation—Epirubicin—urinary bladder cancer	0.000297	0.0009	CcSEcCtD
Almotriptan—Rash—Etoposide—urinary bladder cancer	0.000296	0.000899	CcSEcCtD
Almotriptan—Dermatitis—Etoposide—urinary bladder cancer	0.000296	0.000898	CcSEcCtD
Almotriptan—Headache—Etoposide—urinary bladder cancer	0.000295	0.000893	CcSEcCtD
Almotriptan—Myalgia—Methotrexate—urinary bladder cancer	0.000294	0.000891	CcSEcCtD
Almotriptan—Arthralgia—Methotrexate—urinary bladder cancer	0.000294	0.000891	CcSEcCtD
Almotriptan—Chest pain—Methotrexate—urinary bladder cancer	0.000294	0.000891	CcSEcCtD
Almotriptan—Tension—Doxorubicin—urinary bladder cancer	0.000293	0.000889	CcSEcCtD
Almotriptan—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000293	0.000888	CcSEcCtD
Almotriptan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000292	0.000885	CcSEcCtD
Almotriptan—Malaise—Epirubicin—urinary bladder cancer	0.000291	0.000883	CcSEcCtD
Almotriptan—Discomfort—Methotrexate—urinary bladder cancer	0.00029	0.00088	CcSEcCtD
Almotriptan—Nervousness—Doxorubicin—urinary bladder cancer	0.00029	0.00088	CcSEcCtD
Almotriptan—Vertigo—Epirubicin—urinary bladder cancer	0.00029	0.00088	CcSEcCtD
Almotriptan—Syncope—Epirubicin—urinary bladder cancer	0.00029	0.000878	CcSEcCtD
Almotriptan—Back pain—Doxorubicin—urinary bladder cancer	0.000289	0.000877	CcSEcCtD
Almotriptan—Palpitations—Epirubicin—urinary bladder cancer	0.000285	0.000866	CcSEcCtD
Almotriptan—Confusional state—Methotrexate—urinary bladder cancer	0.000284	0.000861	CcSEcCtD
Almotriptan—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000284	0.000861	CcSEcCtD
Almotriptan—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000282	0.000854	CcSEcCtD
Almotriptan—Vision blurred—Doxorubicin—urinary bladder cancer	0.000282	0.000854	CcSEcCtD
Almotriptan—Convulsion—Epirubicin—urinary bladder cancer	0.00028	0.000849	CcSEcCtD
Almotriptan—Nausea—Etoposide—urinary bladder cancer	0.000279	0.000847	CcSEcCtD
Almotriptan—Hypertension—Epirubicin—urinary bladder cancer	0.000279	0.000846	CcSEcCtD
Almotriptan—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000277	0.000841	CcSEcCtD
Almotriptan—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000276	0.000838	CcSEcCtD
Almotriptan—Arthralgia—Epirubicin—urinary bladder cancer	0.000275	0.000834	CcSEcCtD
Almotriptan—Myalgia—Epirubicin—urinary bladder cancer	0.000275	0.000834	CcSEcCtD
Almotriptan—Chest pain—Epirubicin—urinary bladder cancer	0.000275	0.000834	CcSEcCtD
Almotriptan—Agitation—Doxorubicin—urinary bladder cancer	0.000275	0.000833	CcSEcCtD
Almotriptan—Anxiety—Epirubicin—urinary bladder cancer	0.000274	0.000831	CcSEcCtD
Almotriptan—Skin disorder—Methotrexate—urinary bladder cancer	0.000274	0.00083	CcSEcCtD
Almotriptan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000273	0.000828	CcSEcCtD
Almotriptan—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000272	0.000826	CcSEcCtD
Almotriptan—Discomfort—Epirubicin—urinary bladder cancer	0.000272	0.000824	CcSEcCtD
Almotriptan—Malaise—Doxorubicin—urinary bladder cancer	0.000269	0.000817	CcSEcCtD
Almotriptan—Dry mouth—Epirubicin—urinary bladder cancer	0.000269	0.000816	CcSEcCtD
Almotriptan—Vertigo—Doxorubicin—urinary bladder cancer	0.000268	0.000814	CcSEcCtD
Almotriptan—Syncope—Doxorubicin—urinary bladder cancer	0.000268	0.000813	CcSEcCtD
Almotriptan—Confusional state—Epirubicin—urinary bladder cancer	0.000266	0.000806	CcSEcCtD
Almotriptan—Palpitations—Doxorubicin—urinary bladder cancer	0.000264	0.000801	CcSEcCtD
Almotriptan—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000264	0.000799	CcSEcCtD
Almotriptan—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000263	0.000797	CcSEcCtD
Almotriptan—Shock—Epirubicin—urinary bladder cancer	0.000259	0.000787	CcSEcCtD
Almotriptan—Convulsion—Doxorubicin—urinary bladder cancer	0.000259	0.000785	CcSEcCtD
Almotriptan—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000258	0.000784	CcSEcCtD
Almotriptan—Hypertension—Doxorubicin—urinary bladder cancer	0.000258	0.000783	CcSEcCtD
Almotriptan—Tachycardia—Epirubicin—urinary bladder cancer	0.000257	0.00078	CcSEcCtD
Almotriptan—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000257	0.000778	CcSEcCtD
Almotriptan—Skin disorder—Epirubicin—urinary bladder cancer	0.000256	0.000777	CcSEcCtD
Almotriptan—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000255	0.000773	CcSEcCtD
Almotriptan—Insomnia—Methotrexate—urinary bladder cancer	0.000255	0.000773	CcSEcCtD
Almotriptan—Arthralgia—Doxorubicin—urinary bladder cancer	0.000254	0.000772	CcSEcCtD
Almotriptan—Chest pain—Doxorubicin—urinary bladder cancer	0.000254	0.000772	CcSEcCtD
Almotriptan—Myalgia—Doxorubicin—urinary bladder cancer	0.000254	0.000772	CcSEcCtD
Almotriptan—Anxiety—Doxorubicin—urinary bladder cancer	0.000254	0.000769	CcSEcCtD
Almotriptan—Paraesthesia—Methotrexate—urinary bladder cancer	0.000253	0.000767	CcSEcCtD
Almotriptan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000253	0.000766	CcSEcCtD
Almotriptan—Discomfort—Doxorubicin—urinary bladder cancer	0.000251	0.000762	CcSEcCtD
Almotriptan—Dyspnoea—Methotrexate—urinary bladder cancer	0.000251	0.000762	CcSEcCtD
Almotriptan—Somnolence—Methotrexate—urinary bladder cancer	0.00025	0.000759	CcSEcCtD
Almotriptan—Dry mouth—Doxorubicin—urinary bladder cancer	0.000249	0.000755	CcSEcCtD
Almotriptan—Dyspepsia—Methotrexate—urinary bladder cancer	0.000248	0.000752	CcSEcCtD
Almotriptan—Confusional state—Doxorubicin—urinary bladder cancer	0.000246	0.000746	CcSEcCtD
Almotriptan—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000244	0.00074	CcSEcCtD
Almotriptan—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000243	0.000738	CcSEcCtD
Almotriptan—Fatigue—Methotrexate—urinary bladder cancer	0.000243	0.000737	CcSEcCtD
Almotriptan—Pain—Methotrexate—urinary bladder cancer	0.000241	0.000731	CcSEcCtD
Almotriptan—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.00024	0.000728	CcSEcCtD
Almotriptan—Shock—Doxorubicin—urinary bladder cancer	0.00024	0.000728	CcSEcCtD
Almotriptan—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000239	0.000725	CcSEcCtD
Almotriptan—Insomnia—Epirubicin—urinary bladder cancer	0.000238	0.000723	CcSEcCtD
Almotriptan—Tachycardia—Doxorubicin—urinary bladder cancer	0.000238	0.000722	CcSEcCtD
Almotriptan—Skin disorder—Doxorubicin—urinary bladder cancer	0.000237	0.000719	CcSEcCtD
Almotriptan—Paraesthesia—Epirubicin—urinary bladder cancer	0.000237	0.000718	CcSEcCtD
Almotriptan—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000236	0.000715	CcSEcCtD
Almotriptan—Dyspnoea—Epirubicin—urinary bladder cancer	0.000235	0.000713	CcSEcCtD
Almotriptan—Somnolence—Epirubicin—urinary bladder cancer	0.000234	0.000711	CcSEcCtD
Almotriptan—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000232	0.000704	CcSEcCtD
Almotriptan—Dyspepsia—Epirubicin—urinary bladder cancer	0.000232	0.000704	CcSEcCtD
Almotriptan—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.00023	0.000699	CcSEcCtD
Almotriptan—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000228	0.00069	CcSEcCtD
Almotriptan—Fatigue—Epirubicin—urinary bladder cancer	0.000227	0.000689	CcSEcCtD
Almotriptan—Pain—Epirubicin—urinary bladder cancer	0.000225	0.000684	CcSEcCtD
Almotriptan—Abdominal pain—Methotrexate—urinary bladder cancer	0.000223	0.000675	CcSEcCtD
Almotriptan—Body temperature increased—Methotrexate—urinary bladder cancer	0.000223	0.000675	CcSEcCtD
Almotriptan—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000222	0.000674	CcSEcCtD
Almotriptan—Insomnia—Doxorubicin—urinary bladder cancer	0.000221	0.000669	CcSEcCtD
Almotriptan—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000219	0.000664	CcSEcCtD
Almotriptan—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000217	0.00066	CcSEcCtD
Almotriptan—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000217	0.000659	CcSEcCtD
Almotriptan—Somnolence—Doxorubicin—urinary bladder cancer	0.000217	0.000658	CcSEcCtD
Almotriptan—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000216	0.000654	CcSEcCtD
Almotriptan—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000215	0.000651	CcSEcCtD
Almotriptan—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000211	0.000639	CcSEcCtD
Almotriptan—Fatigue—Doxorubicin—urinary bladder cancer	0.00021	0.000638	CcSEcCtD
Almotriptan—Pain—Doxorubicin—urinary bladder cancer	0.000209	0.000633	CcSEcCtD
Almotriptan—Abdominal pain—Epirubicin—urinary bladder cancer	0.000208	0.000632	CcSEcCtD
Almotriptan—Body temperature increased—Epirubicin—urinary bladder cancer	0.000208	0.000632	CcSEcCtD
Almotriptan—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000208	0.000629	CcSEcCtD
Almotriptan—Asthenia—Methotrexate—urinary bladder cancer	0.000202	0.000613	CcSEcCtD
Almotriptan—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000201	0.00061	CcSEcCtD
Almotriptan—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000199	0.000605	CcSEcCtD
Almotriptan—Pruritus—Methotrexate—urinary bladder cancer	0.000199	0.000604	CcSEcCtD
Almotriptan—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000194	0.000589	CcSEcCtD
Almotriptan—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000193	0.000585	CcSEcCtD
Almotriptan—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000193	0.000585	CcSEcCtD
Almotriptan—Diarrhoea—Methotrexate—urinary bladder cancer	0.000193	0.000585	CcSEcCtD
Almotriptan—Asthenia—Epirubicin—urinary bladder cancer	0.000189	0.000574	CcSEcCtD
Almotriptan—Pruritus—Epirubicin—urinary bladder cancer	0.000186	0.000566	CcSEcCtD
Almotriptan—Dizziness—Methotrexate—urinary bladder cancer	0.000186	0.000565	CcSEcCtD
Almotriptan—Diarrhoea—Epirubicin—urinary bladder cancer	0.00018	0.000547	CcSEcCtD
Almotriptan—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.00018	0.000545	CcSEcCtD
Almotriptan—Vomiting—Methotrexate—urinary bladder cancer	0.000179	0.000543	CcSEcCtD
Almotriptan—Rash—Methotrexate—urinary bladder cancer	0.000178	0.000539	CcSEcCtD
Almotriptan—Dermatitis—Methotrexate—urinary bladder cancer	0.000177	0.000538	CcSEcCtD
Almotriptan—Headache—Methotrexate—urinary bladder cancer	0.000176	0.000535	CcSEcCtD
Almotriptan—Asthenia—Doxorubicin—urinary bladder cancer	0.000175	0.000531	CcSEcCtD
Almotriptan—Dizziness—Epirubicin—urinary bladder cancer	0.000174	0.000529	CcSEcCtD
Almotriptan—Pruritus—Doxorubicin—urinary bladder cancer	0.000173	0.000523	CcSEcCtD
Almotriptan—Vomiting—Epirubicin—urinary bladder cancer	0.000168	0.000508	CcSEcCtD
Almotriptan—Nausea—Methotrexate—urinary bladder cancer	0.000167	0.000507	CcSEcCtD
Almotriptan—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000167	0.000506	CcSEcCtD
Almotriptan—Rash—Epirubicin—urinary bladder cancer	0.000166	0.000504	CcSEcCtD
Almotriptan—Dermatitis—Epirubicin—urinary bladder cancer	0.000166	0.000504	CcSEcCtD
Almotriptan—Headache—Epirubicin—urinary bladder cancer	0.000165	0.000501	CcSEcCtD
Almotriptan—Dizziness—Doxorubicin—urinary bladder cancer	0.000161	0.000489	CcSEcCtD
Almotriptan—Nausea—Epirubicin—urinary bladder cancer	0.000157	0.000475	CcSEcCtD
Almotriptan—Vomiting—Doxorubicin—urinary bladder cancer	0.000155	0.00047	CcSEcCtD
Almotriptan—Rash—Doxorubicin—urinary bladder cancer	0.000154	0.000466	CcSEcCtD
Almotriptan—Dermatitis—Doxorubicin—urinary bladder cancer	0.000154	0.000466	CcSEcCtD
Almotriptan—Headache—Doxorubicin—urinary bladder cancer	0.000153	0.000463	CcSEcCtD
Almotriptan—Nausea—Doxorubicin—urinary bladder cancer	0.000145	0.000439	CcSEcCtD
Almotriptan—CYP2D6—Metabolism—NAT1—urinary bladder cancer	7.61e-05	0.000391	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	7.61e-05	0.000391	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—UGT2B7—urinary bladder cancer	7.57e-05	0.000389	CbGpPWpGaD
Almotriptan—MAOA—Metabolism—GSTT1—urinary bladder cancer	7.43e-05	0.000382	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—SLC19A1—urinary bladder cancer	7.21e-05	0.00037	CbGpPWpGaD
Almotriptan—FMO3—Metabolism—PPARG—urinary bladder cancer	7.1e-05	0.000364	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—PRSS3—urinary bladder cancer	7.03e-05	0.000361	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	6.96e-05	0.000358	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—RBX1—urinary bladder cancer	6.92e-05	0.000355	CbGpPWpGaD
Almotriptan—FMO3—Metabolism—CREBBP—urinary bladder cancer	6.82e-05	0.00035	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—CYP4B1—urinary bladder cancer	6.82e-05	0.00035	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	6.8e-05	0.000349	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—RBX1—urinary bladder cancer	6.78e-05	0.000348	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—TSC1—urinary bladder cancer	6.51e-05	0.000334	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—TYMP—urinary bladder cancer	6.5e-05	0.000334	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	6.45e-05	0.000331	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—NAT1—urinary bladder cancer	6.45e-05	0.000331	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—SLC19A1—urinary bladder cancer	6.44e-05	0.000331	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—TSC1—urinary bladder cancer	6.37e-05	0.000327	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	6.34e-05	0.000326	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	6.27e-05	0.000322	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	6.27e-05	0.000322	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—JAG1—urinary bladder cancer	6.19e-05	0.000318	CbGpPWpGaD
Almotriptan—MAOA—Metabolism—NQO1—urinary bladder cancer	6.17e-05	0.000317	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—JAG1—urinary bladder cancer	6.06e-05	0.000311	CbGpPWpGaD
Almotriptan—MAOA—Neuronal System—HRAS—urinary bladder cancer	6.03e-05	0.00031	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	5.92e-05	0.000304	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	5.9e-05	0.000303	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—NAT2—urinary bladder cancer	5.88e-05	0.000302	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	5.77e-05	0.000296	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	5.64e-05	0.000289	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—TYMP—urinary bladder cancer	5.62e-05	0.000289	CbGpPWpGaD
Almotriptan—FMO3—Metabolism—PTGS2—urinary bladder cancer	5.58e-05	0.000287	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	5.4e-05	0.000277	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	5.31e-05	0.000273	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	5.25e-05	0.00027	CbGpPWpGaD
Almotriptan—HTR1D—GPCR downstream signaling—RHOA—urinary bladder cancer	5.24e-05	0.000269	CbGpPWpGaD
Almotriptan—MAOA—Metabolism—GSTP1—urinary bladder cancer	5.15e-05	0.000264	CbGpPWpGaD
Almotriptan—HTR1B—GPCR downstream signaling—RHOA—urinary bladder cancer	5.13e-05	0.000263	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—NAT2—urinary bladder cancer	5.08e-05	0.000261	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—RRM2—urinary bladder cancer	5.07e-05	0.000261	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	5.03e-05	0.000258	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	5.02e-05	0.000258	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—S100B—urinary bladder cancer	5.02e-05	0.000258	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—TYMP—urinary bladder cancer	5.02e-05	0.000258	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	4.98e-05	0.000256	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—NAT1—urinary bladder cancer	4.98e-05	0.000256	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—S100B—urinary bladder cancer	4.91e-05	0.000252	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	4.89e-05	0.000251	CbGpPWpGaD
Almotriptan—FMO3—Metabolism—PTEN—urinary bladder cancer	4.87e-05	0.00025	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.82e-05	0.000247	CbGpPWpGaD
Almotriptan—MAOA—Metabolism—TYMS—urinary bladder cancer	4.79e-05	0.000246	CbGpPWpGaD
Almotriptan—HTR1D—Signaling by GPCR—RHOA—urinary bladder cancer	4.75e-05	0.000244	CbGpPWpGaD
Almotriptan—MAOA—Metabolism—NCOR1—urinary bladder cancer	4.73e-05	0.000243	CbGpPWpGaD
Almotriptan—MAOA—Metabolism—GSTM1—urinary bladder cancer	4.73e-05	0.000243	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—ENO2—urinary bladder cancer	4.7e-05	0.000241	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—HPGDS—urinary bladder cancer	4.7e-05	0.000241	CbGpPWpGaD
Almotriptan—HTR1B—Signaling by GPCR—RHOA—urinary bladder cancer	4.66e-05	0.000239	CbGpPWpGaD
Almotriptan—FMO3—Metabolism—EP300—urinary bladder cancer	4.64e-05	0.000238	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—TYMP—urinary bladder cancer	4.61e-05	0.000237	CbGpPWpGaD
Almotriptan—HTR1D—GPCR downstream signaling—CXCL8—urinary bladder cancer	4.6e-05	0.000236	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—GSTT1—urinary bladder cancer	4.56e-05	0.000234	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	4.55e-05	0.000234	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—NAT2—urinary bladder cancer	4.54e-05	0.000233	CbGpPWpGaD
Almotriptan—MAOA—Metabolism—GPX1—urinary bladder cancer	4.53e-05	0.000233	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—NCOR1—urinary bladder cancer	4.51e-05	0.000232	CbGpPWpGaD
Almotriptan—HTR1B—GPCR downstream signaling—CXCL8—urinary bladder cancer	4.5e-05	0.000231	CbGpPWpGaD
Almotriptan—MAOA—Metabolism—ERCC2—urinary bladder cancer	4.45e-05	0.000228	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—NCOR1—urinary bladder cancer	4.42e-05	0.000227	CbGpPWpGaD
Almotriptan—HTR1D—GPCR downstream signaling—IL2—urinary bladder cancer	4.39e-05	0.000226	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—RRM2—urinary bladder cancer	4.39e-05	0.000225	CbGpPWpGaD
Almotriptan—HTR1B—GPCR downstream signaling—IL2—urinary bladder cancer	4.3e-05	0.000221	CbGpPWpGaD
Almotriptan—MAOA—Metabolism—MTHFR—urinary bladder cancer	4.18e-05	0.000215	CbGpPWpGaD
Almotriptan—HTR1D—Signaling by GPCR—CXCL8—urinary bladder cancer	4.17e-05	0.000214	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—NAT2—urinary bladder cancer	4.17e-05	0.000214	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	4.1e-05	0.000211	CbGpPWpGaD
Almotriptan—HTR1B—Signaling by GPCR—CXCL8—urinary bladder cancer	4.09e-05	0.00021	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	4.06e-05	0.000209	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—ENO2—urinary bladder cancer	4.06e-05	0.000209	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.04e-05	0.000207	CbGpPWpGaD
Almotriptan—HTR1D—Signaling by GPCR—IL2—urinary bladder cancer	3.99e-05	0.000205	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—TERT—urinary bladder cancer	3.97e-05	0.000204	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	3.94e-05	0.000202	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.92e-05	0.000201	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—RRM2—urinary bladder cancer	3.92e-05	0.000201	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—TYMP—urinary bladder cancer	3.91e-05	0.000201	CbGpPWpGaD
Almotriptan—HTR1B—Signaling by GPCR—IL2—urinary bladder cancer	3.91e-05	0.000201	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—TERT—urinary bladder cancer	3.89e-05	0.0002	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.88e-05	0.000199	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	3.87e-05	0.000199	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—NQO1—urinary bladder cancer	3.79e-05	0.000195	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	3.77e-05	0.000194	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.75e-05	0.000193	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—FGFR3—urinary bladder cancer	3.65e-05	0.000187	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	3.63e-05	0.000186	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—ENO2—urinary bladder cancer	3.63e-05	0.000186	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.6e-05	0.000185	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—RRM2—urinary bladder cancer	3.6e-05	0.000185	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—FGFR3—urinary bladder cancer	3.57e-05	0.000183	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—ESR1—urinary bladder cancer	3.54e-05	0.000182	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—NAT2—urinary bladder cancer	3.53e-05	0.000181	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	3.52e-05	0.000181	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—ESR1—urinary bladder cancer	3.47e-05	0.000178	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.46e-05	0.000178	CbGpPWpGaD
Almotriptan—MAOA—Metabolism—PPARG—urinary bladder cancer	3.39e-05	0.000174	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—ENO2—urinary bladder cancer	3.34e-05	0.000171	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	3.34e-05	0.000171	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—NQO1—urinary bladder cancer	3.27e-05	0.000168	CbGpPWpGaD
Almotriptan—MAOA—Metabolism—CREBBP—urinary bladder cancer	3.26e-05	0.000167	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	3.23e-05	0.000166	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.18e-05	0.000163	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—GSTP1—urinary bladder cancer	3.16e-05	0.000162	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—CREBBP—urinary bladder cancer	3.1e-05	0.000159	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—IGF1—urinary bladder cancer	3.07e-05	0.000157	CbGpPWpGaD
Almotriptan—HTR1D—Signaling by GPCR—EGFR—urinary bladder cancer	3.05e-05	0.000157	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—RRM2—urinary bladder cancer	3.05e-05	0.000157	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—CREBBP—urinary bladder cancer	3.04e-05	0.000156	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—TYMP—urinary bladder cancer	3.02e-05	0.000155	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—IGF1—urinary bladder cancer	3e-05	0.000154	CbGpPWpGaD
Almotriptan—HTR1B—Signaling by GPCR—EGFR—urinary bladder cancer	2.99e-05	0.000153	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—TYMS—urinary bladder cancer	2.94e-05	0.000151	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—NQO1—urinary bladder cancer	2.92e-05	0.00015	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—GSTM1—urinary bladder cancer	2.9e-05	0.000149	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—NCOR1—urinary bladder cancer	2.9e-05	0.000149	CbGpPWpGaD
Almotriptan—HTR1D—Signaling by GPCR—KRAS—urinary bladder cancer	2.88e-05	0.000148	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.84e-05	0.000146	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—ENO2—urinary bladder cancer	2.83e-05	0.000145	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	2.83e-05	0.000145	CbGpPWpGaD
Almotriptan—HTR1B—Signaling by GPCR—KRAS—urinary bladder cancer	2.82e-05	0.000145	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.81e-05	0.000144	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—RHOA—urinary bladder cancer	2.81e-05	0.000144	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—GPX1—urinary bladder cancer	2.78e-05	0.000143	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.77e-05	0.000142	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—RHOA—urinary bladder cancer	2.75e-05	0.000141	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	2.74e-05	0.000141	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	2.73e-05	0.00014	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—ERCC2—urinary bladder cancer	2.73e-05	0.00014	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—NAT2—urinary bladder cancer	2.73e-05	0.00014	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.7e-05	0.000139	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—NQO1—urinary bladder cancer	2.69e-05	0.000138	CbGpPWpGaD
Almotriptan—MAOA—Metabolism—PTGS2—urinary bladder cancer	2.67e-05	0.000137	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.64e-05	0.000136	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—ERBB2—urinary bladder cancer	2.6e-05	0.000134	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—MTHFR—urinary bladder cancer	2.57e-05	0.000132	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—ERBB2—urinary bladder cancer	2.55e-05	0.000131	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—TYMS—urinary bladder cancer	2.54e-05	0.00013	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	2.51e-05	0.000129	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	2.51e-05	0.000129	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.47e-05	0.000127	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—CXCL8—urinary bladder cancer	2.47e-05	0.000127	CbGpPWpGaD
Almotriptan—HTR1D—Signaling by GPCR—HRAS—urinary bladder cancer	2.45e-05	0.000126	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	2.44e-05	0.000125	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—CXCL8—urinary bladder cancer	2.41e-05	0.000124	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—GPX1—urinary bladder cancer	2.4e-05	0.000123	CbGpPWpGaD
Almotriptan—HTR1B—Signaling by GPCR—HRAS—urinary bladder cancer	2.4e-05	0.000123	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	2.36e-05	0.000121	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.36e-05	0.000121	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—IL2—urinary bladder cancer	2.36e-05	0.000121	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—RRM2—urinary bladder cancer	2.35e-05	0.000121	CbGpPWpGaD
Almotriptan—MAOA—Metabolism—PTEN—urinary bladder cancer	2.33e-05	0.000119	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—IL2—urinary bladder cancer	2.31e-05	0.000118	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—CCND1—urinary bladder cancer	2.3e-05	0.000118	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—NQO1—urinary bladder cancer	2.28e-05	0.000117	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—TYMS—urinary bladder cancer	2.27e-05	0.000116	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—CCND1—urinary bladder cancer	2.25e-05	0.000116	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	2.24e-05	0.000115	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	2.24e-05	0.000115	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	2.24e-05	0.000115	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—MMP9—urinary bladder cancer	2.23e-05	0.000115	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—CDKN1A—urinary bladder cancer	2.22e-05	0.000114	CbGpPWpGaD
Almotriptan—MAOA—Metabolism—EP300—urinary bladder cancer	2.22e-05	0.000114	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	2.22e-05	0.000114	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—PTEN—urinary bladder cancer	2.22e-05	0.000114	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.21e-05	0.000113	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—MMP9—urinary bladder cancer	2.18e-05	0.000112	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	2.18e-05	0.000112	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—ENO2—urinary bladder cancer	2.18e-05	0.000112	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—CDKN1A—urinary bladder cancer	2.18e-05	0.000112	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—PTEN—urinary bladder cancer	2.17e-05	0.000111	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—GPX1—urinary bladder cancer	2.15e-05	0.00011	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	2.11e-05	0.000109	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—EP300—urinary bladder cancer	2.11e-05	0.000109	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	2.11e-05	0.000108	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—TYMS—urinary bladder cancer	2.08e-05	0.000107	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—PPARG—urinary bladder cancer	2.08e-05	0.000107	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—EP300—urinary bladder cancer	2.07e-05	0.000106	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	2.06e-05	0.000106	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	2.06e-05	0.000106	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—SRC—urinary bladder cancer	2.06e-05	0.000106	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—SRC—urinary bladder cancer	2.01e-05	0.000103	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—CREBBP—urinary bladder cancer	2e-05	0.000103	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	1.98e-05	0.000102	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—GPX1—urinary bladder cancer	1.97e-05	0.000101	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	1.94e-05	9.95e-05	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.93e-05	9.9e-05	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	1.9e-05	9.75e-05	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—MYC—urinary bladder cancer	1.84e-05	9.46e-05	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.84e-05	9.44e-05	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	1.82e-05	9.35e-05	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—MYC—urinary bladder cancer	1.8e-05	9.26e-05	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—EGFR—urinary bladder cancer	1.8e-05	9.25e-05	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—PPARG—urinary bladder cancer	1.8e-05	9.24e-05	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—TYMS—urinary bladder cancer	1.77e-05	9.07e-05	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—EGFR—urinary bladder cancer	1.76e-05	9.06e-05	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.76e-05	9.03e-05	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	1.75e-05	8.96e-05	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	1.75e-05	8.96e-05	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	1.73e-05	8.87e-05	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—KRAS—urinary bladder cancer	1.7e-05	8.74e-05	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—GPX1—urinary bladder cancer	1.67e-05	8.58e-05	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—KRAS—urinary bladder cancer	1.67e-05	8.56e-05	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	1.64e-05	8.43e-05	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—PTGS2—urinary bladder cancer	1.64e-05	8.41e-05	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—PPARG—urinary bladder cancer	1.61e-05	8.24e-05	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	1.54e-05	7.92e-05	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	1.54e-05	7.92e-05	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—TP53—urinary bladder cancer	1.51e-05	7.77e-05	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—TP53—urinary bladder cancer	1.48e-05	7.61e-05	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—PPARG—urinary bladder cancer	1.48e-05	7.58e-05	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.47e-05	7.53e-05	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—HRAS—urinary bladder cancer	1.45e-05	7.43e-05	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—PTEN—urinary bladder cancer	1.43e-05	7.33e-05	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	1.42e-05	7.28e-05	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—HRAS—urinary bladder cancer	1.42e-05	7.28e-05	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	1.41e-05	7.27e-05	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.36e-05	7e-05	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—EP300—urinary bladder cancer	1.36e-05	6.99e-05	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.35e-05	6.92e-05	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.35e-05	6.92e-05	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.29e-05	6.62e-05	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.27e-05	6.5e-05	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	1.26e-05	6.49e-05	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—PPARG—urinary bladder cancer	1.25e-05	6.42e-05	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—PTEN—urinary bladder cancer	1.23e-05	6.34e-05	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	1.2e-05	6.17e-05	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.19e-05	6.11e-05	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—EP300—urinary bladder cancer	1.18e-05	6.04e-05	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	1.16e-05	5.96e-05	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—PTEN—urinary bladder cancer	1.1e-05	5.66e-05	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—EP300—urinary bladder cancer	1.05e-05	5.39e-05	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—PTEN—urinary bladder cancer	1.01e-05	5.2e-05	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	9.84e-06	5.05e-05	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—EP300—urinary bladder cancer	9.66e-06	4.96e-05	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—PPARG—urinary bladder cancer	9.65e-06	4.96e-05	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	9.27e-06	4.76e-05	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—PTEN—urinary bladder cancer	8.58e-06	4.41e-05	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—EP300—urinary bladder cancer	8.18e-06	4.2e-05	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	7.59e-06	3.9e-05	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—PTEN—urinary bladder cancer	6.62e-06	3.4e-05	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—EP300—urinary bladder cancer	6.32e-06	3.24e-05	CbGpPWpGaD
